Home Cart Sign in  
Chemical Structure| 192705-79-6 Chemical Structure| 192705-79-6

Structure of PD-166866
CAS No.: 192705-79-6

Chemical Structure| 192705-79-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PD 166866 is a selective FGFR tyrosine kinase inhibitor with an IC50 of 52.4 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PD-166866

CAS No. :192705-79-6
Formula : C20H24N6O3
M.W : 396.44
SMILES Code : O=C(NC(C)(C)C)NC1=NC2=NC(N)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3
MDL No. :MFCD12922514
InChI Key :NHJSWORVNIOXIT-UHFFFAOYSA-N
Pubchem ID :5328127

Safety of PD-166866

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of PD-166866

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR1

    FGFR1, IC50:52.4 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 0.1 - 50 μM 24 h To evaluate the cytotoxicity of PD-166866 on HeLa cells, the results showed that the drug significantly reduced cell viability, indicating its anti-proliferative effects. PMC2797793
human induced pluripotent stem cells (hiPSCs) 1 μM 4 days To evaluate the role of PD-166866 in the differentiation of hiPSCs into pancreatic islet-like cells (iPICs), the results showed that PD-166866 played an important role in iPIC differentiation. PMC9814340
Valve interstitial cells (VICs) 1000 nM 2 h To investigate the inhibitory effect of PD-166866 on FGF1- and FGF2-mediated Akt phosphorylation. Results showed that PD-166866 significantly inhibited FGF1- and FGF2-mediated Akt phosphorylation. PMC6537403
Jurkat cells 4 μM 36 h To study the effect of PD-166866 on Jurkat cells, results showed that PD-166866 treatment significantly increased the expression of ATF4. PMC10618259
Oli-neu oligodendrocytes 10 µM 24 h To study the effects of PD166866 and/or IFN β-1a on the proliferation and cytotoxicity of Oli-neu oligodendrocytes. Results showed that PD166866 and IFN β-1a, either alone or in combination, significantly reduced cell proliferation, and PD166866 increased cytotoxicity. PMC9603153

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NCG mice Jurkat cell-derived xenograft model Intraperitoneal injection 30 mg/kg Every 2 days for 14 days To study the effect of PD-166866 on T-ALL cells in vivo, results showed that PD-166866 did not significantly inhibit the growth of T-ALL cells. PMC10618259
Zebrafish Double transgenic zebrafish embryos Tg(tg:mCherry/flk1:EGFP) Embryo media 4 µM 36 to 96 hpf, 36 to 48 hpf, 48 to 72 hpf, 72 to 96 hpf To study the effects of PD166866 on thyroid development, results showed that PD166866 had different effects on thyroid morphology and volume at different time windows. PMC8091578
Mice Colorectal cancer liver metastasis model Intraperitoneal injection 20 mg/kg Once every other day for 3 weeks PD-166866 significantly inhibited the expression of p-FGFR1, p-ERK1/2, EGR1, and FAPα PMC9525122

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.52mL

0.50mL

0.25mL

12.61mL

2.52mL

1.26mL

25.22mL

5.04mL

2.52mL

 

Historical Records

Categories